Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer

Although both surgery and radiation are potential curative options for men with clinically localized prostate cancer, a significant proportion of men with high-risk and locally advanced disease will demonstrate biochemical and potentially clinical progression of their disease. Neoadjuvant systemic therapy before radical prostatectomy (RP) is a logical strategy to improve treatment outcomes for men with clinically localized high-risk prostate cancer. Furthermore, delivery of chemotherapy and other systemic agents before RP affords an opportunity to explore the efficacy of these agents with pathologic end points.Neoadjuvant chemotherapy, primarily with docetaxel (with or without androgen deprivation therapy), has demonstrated feasibility and safety in men undergoing RP, but no study to date has established the efficacy of neoadjuvant chemotherapy or neoadjuvant chemohormonal therapies. Other novel agents, such as those targeting the vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, clusterin, and immunomodulatory therapeutics, are currently under investigation.     

皮下环精索封闭疗法治疗急性附睾-睾丸炎疗效观察

目的评价急性附睾-睾丸炎皮下环精索封闭疗法的疗效.方法对80例急性附睾-睾丸炎病例随机分为两组,对照组给予传统治疗方法,而治疗组除了传统疗法外,加用皮下环精索封闭治疗.结果治疗组所有患者1～3d内发热、疼痛症状缓解,4～6 d内附睾睾丸肿胀明显减退,97.5%的病例2周内治愈;而对照组40%的患者1～3d内发热、疼痛症状缓解,75%的患者4～6d内附睾睾丸肿胀减退,80%患者2周内治愈,治疗组疗效优于对照组.结论皮下环精索封闭疗法可以迅速缓解临床症状,缩短病程,提高治愈率,是治疗急性附睾-睾丸炎的有效方法.     

Experimental studies of chemosensitivity testing of urothelial cancer grown in nude mice

Summary The present study provides information relevant to a number of variables which may influence response to treatment of nude mouse-grown human urothelial cancer. A number of xenotransplanted tumors were exposed to selected treatments at different transplant generations, and at various dose levels and treatment schedules. It was observed that nude mouse-grown tumors were characterized by consistency, reproducibility and biological stability not affected by the transplant generation at which they were examined. Treatment related dose response curves were steep, the sharpness of the curves depending on the degree of tumor sensitivity. Best therapeutic results were obtained at the maximum tolerated dose of cytotoxic agents under study and of importance, a 20% to 40% dose reduction with the same treatment schedule resulted in little or no activity. In addition, treatment schedule, timing and sequence of treatments and to a certain degree, tumor grade were important variables which could influence tumor response. The nude mouse-human tumor system provides important preclinical guidelines on dose, schedule, sequence and timing of treatments and can assist in designing more efficient clinical trials.     

Dermatomyositis in a patient with high grade papillary urothelial carcinoma of urinary bladder

Inflammatory myopathies like dermatomyositis are associated with increased incidence of malignancies. This association has been commonly reported with malignancies of ovaries, gastro‐intestinal tract, breast and non‐Hodgkin's lymphomas but occurrence of dermatomyositis with bladder cancer has been rarely reported. We report a patient with carcinoma bladder who developed dermatomyositis while being treated for the bladder cancer.     

新生儿血糖监测（附32例临床分析）

应用英国产“ＨＹＰＯＣＯＵＮＴＧＡ”微量血糖测定仪（氧化酶光电比色法）对同期住院新生儿不分病种连续３天进行空腹血糖监测。结果在原发疾病情况下表现出低血糖发生频率高，而低血糖症状又被原发疾病所掩盖。在３２例中足月儿２３例，足月小样儿４例，早产儿５例，在３２例９６次监测中发现低血糖１４例，其中足月儿９例，早产儿５例．发病率为４３．７％；高血糖３例。无一例死亡。提示：新生儿患病情况下，易发生低血糖，其发生与疾病、孕周有关而与体重无关。因此，在新生儿期必须注意及时喂养与补充葡萄糖，防止低血糖时间过长对脑部造成损伤。     

Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users

The introduction of highly active antiretroviral therapy (HAART) has resulted in marked reductions in mortality and acquired immunodeficiency syndrome (AIDS) incidence across all risk groups; however, the proportionate decrease among injecting drug users (IDUs) has been less impressive. Much of the disparity in benefit to IDUs has been a consequence of decreased access to and receipt of potent antiretroviral combinations. Strategies to increase access to and utilization of HAART have included entry into drug treatment and abstinence. Unfortunately, as few as 15%–20% of active drug users in the United States, and in many other countries, are in drug treatment at any one time. We report a pilot project among out-of-drug treatment IDUs infected with human immunodeficiency virus (HIV); HIV therapy was successfully provided to active heroin injectors using the Community Health Care Van (CHCV) at sites of needle exchange. Subjects were willing to initiate, but were not receiving, recommended HIV therapy and were not interested in formal drug treatment. Antiretroviral therapy regimens were selected and linked to heroin injection timing. Weekly visits were scheduled by CHCV staff to assess adverse side effects and encourage adherence. Of the 13 participants, the mean baseline HIV-1 RNA level and CD4 lymphocyte count were 162,369 (log 5.21) copies per milliliter and 265 cells per milliliter, respectively. By 6 months, the proportion whose HIV-1 RNA was below the limits of detection (<400 copies/mL) was 85% (N=11); 77% (N=10) had nondetectable levels by 9 months. By 12 months, 54% (N=7) had a persistently nondetectable viral load, and the net increase in CD4 lymphocyte count was 150 cells per milliliter. As an additional and unintended benefit of this pilot project, 9 (69%) subjects chose to enter drug treatment after achieving a nondetectable viral load. Entry into drug treatment was associated with durability of viral suppression. This small pilot study suggests that health services based on needle exchange may enhance access to HAART among out-of-treatment HIV-infected IDUs. In addition, it demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention.     

甲酰肽受体家族受体与恶性肿瘤

甲酰肽受体家族受体包括甲酰肽受体（FPR）、类甲酰肽受体1和类甲酰肽受体2是主要表达在吞噬细胞表面的一类七次跨膜、G蛋白偶联受体。这些受体被相应的激动剂激活后，能活化吞噬细胞，引起细胞的趋化移动和炎症介质的释放等生物学效应，从而在天然免疫和炎症反应中发挥重要作用。近年来，人们发现甲酰肽受体家族受体也高表达于某些恶性肿瘤细胞的表面，且与这些肿瘤的发生、发展、转移以及治疗有着密切的关系，这无疑揭示了甲酰肽受体家族受体一个新的重要作用，值得深入研究和探讨。     

躯体形式障碍的治疗分析

目的探讨躯体形式障碍的治疗方法。方法用钟友彬的认识领悟疗法对躯体形式障碍3案例治疗通程予以报告和分析。结果认识领悟疗法对躯体形式障碍有一定的临床治疗效果。结论认识领悟疗法治疗躯体形式障碍是有效的和可行的。     

西拉普利和氨氯地平治疗原发性高血压的临床对照研究

目的探讨西拉普利治疗原发性高血压的临床疗效和安全性。方法采用随机对照的方法,分别用西拉普利和氨氯地平治疗92例原发性高血压患者。观察药物治疗后8周内血压、心率的变化。结果服药8周后西拉普利组总有效率85．4％,收缩压和舒张压分别由治疗前的(20．4±1．8)kPa和(13．7±1．3)kPa降至治疗后的(17．4±1．7)kPa和(11．9±1．1)kPa;氨氯地平组总有效率为88．6％,收缩压和舒张压分别由治疗前的(20．5±1．7)kPa和(13．5±1．6)kPa降至治疗后的(17．3±1．7)kPa和(11．8±1．2)kPa,两组比较无统计学意义。患者用药后无严重的不良反应。结论西拉普利是一种安全和有效的治疗轻中度原发性高血压的药物。     

钝性剥离术治疗71例肝海绵状血管瘤

目的探讨采用包膜外钝性剥离法切除肝海绵状血管瘤的治疗经验。方法分析总结作者在肝门阻断下采用包膜外钝性剥离法切除71例肝海绵状血管瘤患者的临床资料。结果全部病例手术经过顺利,术中出血少,术后恢复良好,并发症低于其他术式。结论包膜外钝性剥离治疗肝海绵状血管瘤是一种安全、简便、有效且创伤小的手术方式